Extracorporeal anticoagulation
0 original drugs 0
Novel Drugs
11
Reformulations
0
Active Trials
0
Drug Targets
Extracorporeal anticoagulation has 0 FDA-approved novel treatments. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.
Novel Extracorporeal anticoagulation Drugs by Company (New molecular entities)
No novel drugs found for this indication.
Reformulations (11 drugs) Click to expand
Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.
ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN
T5 1993
DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN
T5 1988
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN
T5 1988
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN
T5 1988
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER
Baxter
T5 1982
DEXTROSE 70% IN PLASTIC CONTAINER
B BRAUN
T5 1979
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Baxter
T5 1979
DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER
Baxter
T5 1979
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ
Baxter
T5 1979
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ
Baxter
T5 1979
DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
Baxter
T5 1970
Generic Drugs (2 ANDA approved) Click to expand
Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs